Free radical peroxidation products in cerebrospinal fluid and serum of patients with multiple sclerosis after glucocorticoid therapy

Folia Neuropathologica

Volumn 48, Issue 2, 2010, Pages 116-122

  Mitosek Szewczyk, Krystyna ^a   Gordon Krajcer, Wanda ^b   Walendzik, Piotr ^b   Stelmasiak, Zbigniew ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Free radical peroxidation; Glucocorticoid therapy; Methylprednisolone; Multiple sclerosis

Indexed keywords

FREE RADICAL; METHYLPREDNISOLONE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THIOL DERIVATIVE; COPPER ZINC SUPEROXIDE DISMUTASE; GLUCOCORTICOID;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; PEROXIDATION; REMISSION; SERUM; BLOOD; DRUG EFFECTS; LIPID PEROXIDATION; METABOLISM; PHYSIOLOGY;

ADULT; FEMALE; FREE RADICALS; GLUCOCORTICOIDS; HUMANS; LIPID PEROXIDATION; MALE; METHYLPREDNISOLONE; MULTIPLE SCLEROSIS; SULFHYDRYL COMPOUNDS; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 77954725155     PISSN: 16414640     EISSN: 1509572X     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Airla N, Luomala M, Elovaara I, Kettunen E, Knuutila S, Lehtimäki T. Suppresion of immune system genes by methylpred-nisolone in exacerbations of multiple sclerosis. Preliminary results. J Neurol 2004; 251: 215-219.
2. Aizenman E, Hartnett KA, Reynolds IJ. Oxigen free radicals regulate NMDA receptor function via a redox modulatory site. Neuron 1990; 5: 841-846.
3. Arundhati J, Kalipada P Oxidative stress kills human primary oligodendrcytes via neural sphingomyelinase: implication for multiple sclerosis. J Neuroimmune Pharmacol 2007; 2: 184-193.
4. Dufour A, Salmaggi A, La Mantia L, Eoli M, Nepolo A, Milanese C. High-dose methylprednisolone treatment-induced changes in immunological parameters in progressive MS patients. Int J Neurosci 1994; 75: 119-128. (Pubitemid 2072090)
5. Frequin ST, Lamers KJ, Borm GF, Barkhof F, Jongen PJ, Holmmes OR. T-cell subsets in the cerebrospinal fluid and peripheral blood of multiple sclerosis patients treatment with high-dose intravenous methylprednisolone. Acta Neurol Scand 1993; 88: 80-86. (Pubitemid 23247967)
6. Forman HJ, Fisher AB. Role of glutathione peroxidase in tolerance and adaptation of rats to hyperoxia. In: Bors W, Saran M, Tait D (eds.). Oxygen Radicals in Chemistry and Biology. Walter de Gruyter, Berlin, New York 1984; pp. 699-704.
7. Frohman EM, Racke MK, Raine CS. Multiple sclerosis - the plaque and its pathogenesis. N Engl J Med 2006; 354: 942-955.
8. Gallo P, Chiusole M, Sanzari M, Sivieri S, Piccinno MG, Argentiero V, Rizzotti P, Tavolato B. Effect of high-dose steroid therapy on T-cell subpopulations. A longitudinal study in MS patients. Acta Neurol Scand 1994; 89: 95-101.
9. Gelati M, Corsini E, Durfour A, Ciusani E, Massa G, Frigerio S, Milanese C, Nespolo A, Salmaggi A. Reduced adhesion of PBM-NCs to endothelium in methylprednisolone-treated MS patients: preliminary results. Acta Neurol Scand 1997; 96: 283-292. (Pubitemid 27512501)
10. Gsell W, Conrad R, Hickethier M, Sofic E, Frölich L, Wichart I, Jellinger K, Moll G, Ransmayr G, Beckmann H, Riederer P. Decrease catalase activity but unchanged superoxide dismutase activity in brains of patients with dementia of Alzheimer type. J Neurochem 1995; 64: 1216-1223.
11. Han MH, Hwang SI, Roy DB, Lundgren DH, Price JV, Ousman SS, Fernald GH, Gerlitz B, Robinson WH, Baranzini SE, Grinnell BW, Raine CS, Sobel RA, Han DK, Steinman L. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 2008; 451: 1076-1081.
12. Hossmann KA. Pathophysiological basis of translational stroke research. Folia Neuropathol 2009; 47: 213-227.
13. Hunter MIS, Nlemadim BC, Davidson DLW. Lipid peroxidation products and antioxidant proteins in plasma and cerebrospinal fluids from multiple sclerosis patients. Neurochem Res 1985; 10: 1645-1652.
14. Jana A, Pahan K. Oxidative stress kills human primary oligodendrocytes via neutral sphingomyelinase: implications for multiple sclerosis. J Neuroimmune Pharmacol 2007; 2: 184-193.
15. Kirk P, Compston A. The effect of methylprednisolone on lymphocyte phenotype and function in patients with multiple sclerosis. J Neuroimmunol 1990; 26: 1-8. (Pubitemid 20002885)
16. Koch M, Mostert J, Arutjunyan AV, Stepanov M, Teelken A, Heersema D, De Keyser J. Plasma lipid peroxidation and progression of disability in multiple sclerosis. Eur J Neurol 2007; 14: 529-533. (Pubitemid 46587841)
17. Kramer JH, Misik V, Weglicki WB. Lipid peroxidation-derived free radical production and postischemic myocardial reperfusion injury. Ann NY Acad Sc 1994; 723: 180-196.
18. Kurtzke JE. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
19. Lei SZ, Pan ZH, Aggarwal SK, Chen HSV, Hartman J, Sucher N, Lipton SA. Effects of nitrate oxide production on the redox modulatory site of the NMDA receptor-channel complex. Neuron 1992; 8: 1087-1099.
20. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
21. Love S, Jenner P. Oxidative stress in neurological disease. Brain Pathol 1999; 9: 55-56.
22. Lung DY, Bloom JW. Update on glucocorticoid action and resistance. J Allergy Clin Immunol 2003; 111: 3-22.
23. Martínez-Cáceres EM, Barrau MA, Brieva L, Espejo C, Barberá N, Montalban X. Treatment with methylprednisolone in relapse of multiple sclerosis patients: immunological evidence of immediate and short-term but not long-lasting effects. Clin Exp Immunol 2002; 127: 165-171. (Pubitemid 34155472)
24. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, MaFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, von den Noot S, Weinshenker BY, Wolinsky JS. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
25. Meister A, Anderson ME. Glutathione. Annu Rev Biochem 1983; 52: 711-760.
26. Michałowska-Wender G, Wender M. Peripheral blood cell immunomarkers in the course of methylprednisolone treatment of multiple sclerosis relapses. Folia Neuropathologica 2008; 46: 134-138.
27. Misra HP, Fridovich J. The role of superoxide anion in the autooxidation of epinephrine and simple assay for superoxide dismutase. J Biol Chem 1972; 247: 3170-3175.
28. Naidoo R, Knapp ML. Studies of lipid peroxidation products in cerebral fluid and serum in multiple sclerosis and other conditions. Clin Chem 1992; 38: 2449-2454. (Pubitemid 23006211)
29. Orrenius S, Burkitt MJ, Kass GEN, Dypbukt J, Nicotera P. Calcium ions and oxidative cell injury. Ann Neurol 1992; 32: S33-42.
30. Ortiz GG, Macías-Islas MA, Pacheco-Moisés FP, Cruz-Ramos JA, Sustersik S, Barba EA, Aguayo A. Oxidative stress is increased in serum from Mexican patients with relapsing-remitting multiple sclerosis. Dis Markers 2009; 26: 35-39.
31. Percy ME, Dalton AJ, Markovic VD, Crapper McLachlan DR, Hummel JT, Rusk ACM, Andrews DF. Red cell superoxide dismutase, glutathione peroxidase and catalase in Down Syndrome patients with and without manifestations of Alzheimer disease. Am J Med Gen 1990; 35: 459-467.
32. Perumal JS, Caon C, Hreha S, Zabad R, Tselis A, Lisak R, Khan O. Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis. Eur J Neurol 2008; 15: 677-680. (Pubitemid 351814399)
33. Placer Z, Cushman L, Johnson B. Estimation of product of lipid peroxidation malondialdehyde in biochemical systems. Anal Bioch 1966; 16: 359-364.
34. Raine CS. Multiple sclerosis: classification revisited reveals homogeneity and recapitulation. Ann Neurol 2008; 63: 1-3.
35. Rehncrona S, Folbergrova J, Smith DS, Siesjo BK. Influence of complete and pronounced incomplete cerebral ischemia and subsequent recirculation on cortical concentracions of oxidized and reduced glutathione in the rat. Neurochem 1980; 34: 477-486. (Pubitemid 10165060)
36. Sedlak J, Lindsay RH. Estimation of total protein bound and non-protein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem 1968; 25: 192-205.
37. Selmaj K, Jurewicz A, Matysiak M, Raine CS. Soluble Nogo-A in CSF is not a usefule biomarker for multiple sclerosis. Neurology 2009; 72: 1708-1709.
38. Slater TF, Sawyer BC. The stimulatory effects of carbon tetrachloride and other halogenoalkanes on peroxidative reactions in rat liver fractions in vitro. Biochem J 1971; 123: 805-814.
39. Slivka A, Mytilineou C, Cohen G. Histochemical evaluation of glutathione in brain. Brain Res 1987; 409: 275-284.
40. Smith J, Kapoor R, Felts PA. Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol 1999; 9: 69-92. (Pubitemid 29056521)
41. Southorn PA, Powis G. Free radicals in medicine. Chemical nature and biologic reactions. Mayo Clin Proc 1998; 63a: 381-389.
42. Sulkowski G, Da̧browska-Bouta B, Kwiatkowska-Patzer B, Strużyńska L. Alterations in glutamate transport and group I metabotropic glutamate receptors in the rat brain during acute phase of experimental autoimmune encephalomyelitis. Folia Neuropathol 2009; 47: 329-337.
43. Van Horssen J, Schreibelt G, Drexhage J, Hazes T, Dijkstra CD, van der Valk P, de Vries HE. Severe oxidative damage in multiple sclerosis lesions coincidences with enhanced antioxidant enzyme expression. Free Radic Biol Med 2008; 45: 1729-1737.
44. Wilson JX. Antioxidant defense of the brain: a role for astrocytes. Can J Physiol Pharmacol 1997; 75: 1149-1163.